Author: Editor

In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Ruben A. Mesa discusses the pros and cons of therapy for “early” myelofibrosis. Earn accreditation for a related activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Gunnar BirgegÃ¥rd discusses what we have learned so far regarding the use of JAK inhibitors in the treatment of essential thrombocythemia (ET) and polycythemia vera (PV). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Jean-Jacques Kiladjian provides and update on long-acting interferons for the treatment of myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Michael Kroll discusses the diagnosis and treatment of splanchnic vein thrombosis and myeloproliferative neoplasms (MPN).

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Tiziano Barbui discusses the updated World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Rajko Kuec discusses the interplay of somatic and germline variants in myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Marie-Caterine Le Bousse-Kerdilès discusses cytokines, cells, and inflammation in myeloproliferative neoplasms (MPN). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Mario Cazzola discusses somatic mutations of RNA splicing machinery in myelodysplastic syndromes (MDS). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Carol Gambacorti-Passerini discusses the genetic basis of atypical chronic myeloid leukemia (CML). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Eric Solary discusses the genetic basis of chronic myelomonocytic leukemia (CMML). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

This discussion between the chairs of the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes” provides a summary of the most intriguing and clinically applicable topics and data, outlines key learning points, and reinforces the take-home messages from the Congress. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Alessandro M. Vannucchi argues that early-stage myelofibrosis should be treated. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Paola Guglielmelli discusses the clinical benefit of JAK2 inhibitors in patients with myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Franscisco Cervantes discusses emerging JAK2 inhibitor combination treatment strategies for patients with myelofibrosis. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Mario Cazzola argues that early-stage myelofibrosis should be not treated but should be observed. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

Metastatic Colorectal Cancer” symposium, Eric Van Cutsem discusses the emerging treatment options for metastatic colorectal cancer patients in the late-line setting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7200 © 2016 Imedex, LLC.

In this presentation from the “Individualizing Late-Line Treatment for Patients with Metastatic Colorectal Cancer” symposium, Dr. Howard S. Hochster discusses the management of adverse events associated with third-line treatments for metastatic colorectal cancer. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7200 © 2016 Imedex, LLC.

This discussion presents a discussion between world-renowned thought leaders Axel Grothey, Howard Hochster, and Eric Van Cutsem, who elucidate the effective implementation of new late-line CRC treatments in the clinical setting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7199 © 2016 Imedex, LLC.

In this webcast, Dr. David P. Steensma discusses the most pertinent information presented on leukemia and myeloid disorders during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this webcast, Dr. John P. Leonard discusses the most pertinent information presented on lymphoma during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this webcast, Dr. Robert Z. Orlowski discusses the most pertinent information presented on multiple myeloma during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

Advancements in breast cancer care continue to rapidly evolve and the San Antonio Breast Cancer Symposium (SABCS) is the premier annual forum for exchange of new scientific and clinical information. However, not all healthcare professionals have the opportunity to attend this meeting and even those that do attend often can benefit from taking a deeper dive into the relevance of the data in a smaller venue in which more intimate faculty and peer interactions can take place. This is the role of the annual Best of San Antonio – Breast Cancer: Bench to Bedside meetingto help practicing clinicians interpret the…

Polycythemia vera (PV) is characterized by erythrocytosis, thrombocytosis, and/or leukocytosis with a broad-range of disease-related symptoms that impact the overall health and everyday quality of life of patients. The identification of the high frequency JAK2V617F mutation in patients with PV defines a molecular target for therapeutic intervention. This interactive case-based activity, is designed to complement, accelerate, and reinforce application of knowledge and skills amongst healthcare professionals interested in optimal management strategies for patients with PV. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7194 © 2016 Imedex, LLC.

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen receptor-positive (ER+) metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for this use. This activity discusses the ongoing and planned clinical trials for abemaciclib and ribociclib in ER+ metastatic breast cancer, as well as the future implications for this class of agents in this patient population. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7171 © 2016 Imedex, LLC.

Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen ER+ metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for breast cancer. This activity discusses clinical data on the efficacy and safety of the FDA-approved CDK 4/6 inhibitor, palbociclib, in combination with letrozole in ER+ metastatic breast cancer. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7170 © 2016 Imedex, LLC.

The cyclin-dependent kinase (CDK) pathway is critical to cell cycle entry. In many tumor types, including breast cancer, there is dysregulation of this pathway. This activity describes the rationale and mechanism for inhibiting this dysregulated pathway in estrogen receptor-positive (ER+) metastatic breast cancer using selective CDK 4/6 inhibitors. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7169 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Paul Baas discusses updates in the systemic treatment of pleural mesothelioma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Elisabeth Quoix discusses the optimatl treatment of elderly patients with non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Maurice Perol discusses the targeting of angiogenesis for the treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses the maintenance paradigm for the treatment of non-squamous non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses the first- and second-generation ALK inhibitors for the treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Rafal Dziadziuszko discusses strategies for overcoming KRAS mutations. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses extreme rare mutations in lung cancer (ROS1, TRK, HER2) and the treatment opportunities available for them. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Nicholas Girard discusses the mechanisms of resistance to EGFR TKIs and new treatment strategies for combating this resistance. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Guilio Rossi discusses the an algorithm for molecular testing of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Gosney discusses the inherent challenges faced by the pathologist in the era of personalized medicine. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses response criteria and kinetics with the use of immunocheckpoint inhibitors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses how biomarkers predict the clinical activity of immunocheckpoints. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. David Waller argues that surgery is the treatment of choice for Stage 1 non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Umberto Ricardi argues that steretactic body radiation therapy (SBRT) is the treatment of choice for Stage 1 non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Vansteenkiste discusses the current status of adjuvant thereapy for the treatment of non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Richard Booton discusses the use of endobronchial and other techniquces to opmize the diagnosis and treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses new proposals for a new TNM classification for lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Klaus Irion discusses the use of diagnotics for the staging of lung cancer including the use of functional imaging and volumetric assessment. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. John P. Leonard argues that watch and wait may still be utilized in cases of follicular lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michael E. Williams argues that “watch and wait” should not be utilized in the treatment of follicular lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Andrew M. Evens discusses the latest in the initial management of Hodgkin lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Morton Coleman argues that one should not utilize surveillance imagine for diffuse large b-cell lymphoma (DLBCL) patients in remission. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michell R. Smith argues that we should utilze surveillance imaging for diffuce large b-cell lymphoma (DLBCL) patients who are in remission. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Tracy Batchelor discusses the latest updates in primary CNS lymphoma management. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.